Clinical Trial Update: Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review

View source ↗

Summary

This completed retrospective chart review investigated treatment patterns and healthcare resource use in acute myeloid leukemia with or without FLT3 mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Acute Myeloid Leukemia (AML) | Status: COMPLETED